Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple.

Similar presentations


Presentation on theme: "A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple."— Presentation transcript:

1 A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple Myeloma  Luciano J. Costa, Heather Landau, Saurabh Chhabra, Parameswaran Hari, Racquel Innis-Shelton, Ayman Saad, Donna Salzman, Mehdi Hamadani, Roni Tamari, Lisa Williams, Evelyn Orlando, Pamela Dixon, Sergio A. Giralt  Biology of Blood and Marrow Transplantation  Volume 23, Issue 3, Pages S81-S82 (March 2017) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 Phase 1 treatment scheme.
Biology of Blood and Marrow Transplantation  , S81-S82DOI: ( /j.bbmt ) Copyright © Terms and Conditions

3 Figure 2 MM disease assessment before and 100 days after K-Mel auto-HCT. Biology of Blood and Marrow Transplantation  , S81-S82DOI: ( /j.bbmt ) Copyright © Terms and Conditions

4 Figure 3 PFS of relapsed MM patients undergoing K maintenance after K-Mel auto-HCT. Biology of Blood and Marrow Transplantation  , S81-S82DOI: ( /j.bbmt ) Copyright © Terms and Conditions


Download ppt "A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple."

Similar presentations


Ads by Google